Unknown

Dataset Information

0

Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity.


ABSTRACT: 5-hydroxytryptamine receptor (5-HT(4)R) agonists promote gastrointestinal motility and attenuate visceral pain, but concerns about adverse reactions have restricted their availability. We tested the hypotheses that 5-HT(4) receptors are expressed in the colonic epithelium and that 5-HT(4)R agonists can act intraluminally to increase motility and reduce visceral hypersensitivity.Mucosal expression of the 5-HT(4)R was evaluated by reverse-transcriptase polymerase chain reaction and immunohistochemical analysis of tissues from 5-HT(4)R(BAC)-enhanced green fluorescent protein mice. Amperometry, histology, and short-circuit current measurements were used to study 5-HT, mucus, and Cl(-) secretion, respectively. Propulsive motility was measured in guinea pig distal colon, and visceromotor responses were recorded in a rat model of colonic hypersensitivity. 5-HT(4)R compounds included cisapride, tegaserod, naronapride, SB204070, and GR113808.Mucosal 5-HT(4) receptors were present in the small and large intestines. In the distal colon, 5-HT(4) receptors were expressed by most epithelial cells, including enterochromaffin and goblet cells. Stimulation of 5-HT(4)Rs evoked mucosal 5-HT release, goblet cell degranulation, and Cl(-) secretion. Luminal administration of 5-HT(4)R agonists accelerated propulsive motility; a 5-HT(4)R antagonist blocked this effect. Bath application of 5-HT(4)R agonists did not affect motility. Oral or intracolonic administration of 5-HT(4)R agonists attenuated visceral hypersensitivity. Intracolonic administration was more potent than oral administration, and was inhibited by a 5-HT(4)R antagonist.Mucosal 5-HT(4) receptor activation can mediate the prokinetic and antinociceptive actions of 5-HT(4)R agonists. Colon-targeted, intraluminal delivery of 5-HT(4)R agonists might be used to promote motility and alleviate visceral pain, while restricting systemic bioavailability and resulting adverse side effects.

SUBMITTER: Hoffman JM 

PROVIDER: S-EPMC3477545 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity.

Hoffman Jill M JM   Tyler Karl K   MacEachern Sarah J SJ   Balemba Onesmo B OB   Johnson Anthony C AC   Brooks Elice M EM   Zhao Hong H   Swain Greg M GM   Moses Peter L PL   Galligan James J JJ   Sharkey Keith A KA   Greenwood-Van Meerveld Beverley B   Mawe Gary M GM  

Gastroenterology 20120104 4


<h4>Background & aims</h4>5-hydroxytryptamine receptor (5-HT(4)R) agonists promote gastrointestinal motility and attenuate visceral pain, but concerns about adverse reactions have restricted their availability. We tested the hypotheses that 5-HT(4) receptors are expressed in the colonic epithelium and that 5-HT(4)R agonists can act intraluminally to increase motility and reduce visceral hypersensitivity.<h4>Methods</h4>Mucosal expression of the 5-HT(4)R was evaluated by reverse-transcriptase pol  ...[more]

Similar Datasets

| S-EPMC2806102 | biostudies-literature
| S-EPMC8532042 | biostudies-literature
| S-EPMC8229129 | biostudies-literature
| S-EPMC9420680 | biostudies-literature
| S-EPMC3051389 | biostudies-literature
| S-EPMC5914911 | biostudies-literature
| S-EPMC6124407 | biostudies-literature
| S-EPMC3504740 | biostudies-literature
| S-EPMC6214663 | biostudies-literature
| S-EPMC6657407 | biostudies-literature